Vor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbush
Wedbush has reiterated an "outperform" rating for Vor Biopharma (NYSE:VOR) with a price target of $XX. Other analysts, including Robert W. Baird and JMP Securities, have also issued positive ratings and price targets. Vor Biopharma's stock rose 14.9% recently, trading at $XX. The company reported earnings per share of $(XX), meeting estimates. Institutional investors hold 97.29% of the stock, and Vor Biopharma is focused on developing treatments for acute myeloid leukemia and other hematological malignancies.
Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "outperform" rating restated by research analysts at Wedbush in a report issued on Friday,RTT News reports. They currently have a $11.00 target price on the stock.
Get Vor Biopharma alerts:
A number of other research analysts have also issued reports on VOR. Robert W. Baird reduced their price objective on Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating for the company in a research report on Friday. JMP Securities restated a "market outperform" rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday, September 6th. Barclays reduced their price objective on Vor Biopharma from $10.00 to $3.00 and set an "overweight" rating for the company in a report on Wednesday, August 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $17.50 price target on shares of Vor Biopharma in a research report on Friday. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vor Biopharma has an average rating of "Buy" and an average target price of $11.36.
View Our Latest Stock Analysis on VOR
Vor Biopharma Stock Up 14.9 %
Vor Biopharma stock traded up $0.12 during mid-day trading on Friday, reaching $0.96. 781,468 shares of the company's stock traded hands, compared to its average volume of 504,849. The stock has a 50 day moving average of $0.80 and a two-hundred day moving average of $1.08. The company has a market cap of $65.53 million, a price-to-earnings ratio of -0.55 and a beta of -0.40. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $3.14.
Vor Biopharma (NYSE:VOR - Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, meeting the consensus estimate of ($0.41). As a group, sell-side analysts forecast that Vor Biopharma will post -1.51 earnings per share for the current year.
Institutional Investors Weigh In On Vor Biopharma
Several institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC lifted its holdings in shares of Vor Biopharma by 51.4% during the second quarter. Acadian Asset Management LLC now owns 81,305 shares of the company's stock valued at $79,000 after acquiring an additional 27,597 shares during the period. Hsbc Holdings PLC lifted its position in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company's stock worth $51,000 after buying an additional 31,333 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Vor Biopharma by 40.8% during the third quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company's stock worth $116,000 after acquiring an additional 48,017 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Vor Biopharma during the second quarter worth approximately $53,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vor Biopharma during the second quarter valued at approximately $63,000. Institutional investors and hedge funds own 97.29% of the company's stock.
About Vor Biopharma
(Get Free Report)Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Read More
- Five stocks we like better than Vor Biopharma
- Why Invest in High-Yield Dividend Stocks?
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- How to Use Stock Screeners to Find Stocks
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Industrial Products Stocks Investing
- The Top 5 Performing S&P 500 Stocks YTD in 2024
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Why buying gold might be a mistake (From DTI) (Ad)
Should you invest $1,000 in Vor Biopharma right now?
Before you consider Vor Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vor Biopharma wasn't on the list.
While Vor Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
